# **Special Issue**

# Clinical Therapeutics of Nonsmall Cell Lung Cancer

### Message from the Guest Editors

The recent development of less-invasive surgical techniques such as video-assisted, robot-assisted, and port-reduced thoracic surgery for non-small-cell lung cancer (NSCLC) has made remarkable progress in efficacy and safety. Targeted therapies for metastatic or advanced NSCLCs have also shown remarkable development. Recent guideline-consistent recommendations are to check for driver gene mutations or PD-L1 status for those NSCLCs. As for the perioperative treatment of NSCLC, molecular targeted medicine and immune-checkpoint inhibitors are to be considered instead of conventional chemotherapy and chemoradiotherapy. For example, in the ADAURA clinical trial (NCT02511106), adjuvant osimertinib conferred a significant survival benefit in patients with IB to IIIA EGFR-mutation-positive NSCLC. Therefore, the application of these targeted drugs to earlier stages with completely resectable NSCLCs might confer a surprising survival benefit. The focus of this Special Issue will be current outcomes or featured topics concerning the surgical treatment of NSCLCs in conjunction with analyses of cancer microenvironments.

### **Guest Editors**

Dr. Hiroaki Kuroda

Aichi Cancer Center Hospital, Nagoya, Japan

Dr. Katsuhiro Masago

Aichi Cancer Center Hospital, Nagoya, Japan

Prof. Dr. Hirokazu Matsushita

Aichi Cancer Center Research Institute, Nagoya, Japan

## Deadline for manuscript submissions

closed (30 April 2022)



# Medicina

an Open Access Journal Published by MDPI

Impact Factor 2.4
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/97060

Medicina Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 medicina@mdpi.com

mdpi.com/journal/medicina





# Medicina

an Open Access Journal Published by MDPI

Impact Factor 2.4 CiteScore 4.1 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

### **Editor-in-Chief**

Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

### **Journal Rank:**

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

